瑞舒伐他汀使用与血尿及蛋白尿风险的关联
基于2011至2019年电子健康记录,分析瑞舒伐他汀与阿托伐他汀新使用者,采用逆概率治疗加权估计血尿、蛋白尿及肾衰竭替代治疗风险。瑞舒伐他汀与血尿、蛋白尿及肾衰竭替代治疗风险升高相关,eGFR<30 ml/min per 1.73 m2者中44%处方日剂量超过FDA推荐的10 mg。
要点
- 与阿托伐他汀相比,瑞舒伐他汀与血尿风险升高相关(HR 1.08,95%CI 1.04-1.11)。
- 与阿托伐他汀相比,瑞舒伐他汀与蛋白尿风险升高相关(HR 1.17,95%CI 1.10-1.25)。
- eGFR<30 ml/min per 1.73 m2者中44%处方瑞舒伐他汀日剂量超过FDA推荐的10 mg。
核心结论
- 与阿托伐他汀相比,瑞舒伐他汀与血尿、蛋白尿及肾衰竭替代治疗风险升高相关。
- eGFR<30 ml/min per 1.73 m2者中44%处方日剂量超过FDA推荐的10 mg。
- 作者认为在处方和监测瑞舒伐他汀时需要更加谨慎,尤其是接受高剂量或患有严重慢性肾脏病的患者。
研究设计与样本
- 使用去标识电子健康记录数据,分析2011至2019年瑞舒伐他汀新使用者152,101例和阿托伐他汀新使用者795,799例。
- 估计逆概率治疗加权后的血尿、蛋白尿及肾衰竭替代治疗风险比(HR)。
- 报告不同eGFR类别下瑞舒伐他汀初始剂量,并评估剂量对血尿和蛋白尿的影响。
主要发现
- 中位随访3.1年期间,共识别血尿患者2.9%、蛋白尿患者1.0%。
- 与阿托伐他汀相比,瑞舒伐他汀与血尿风险升高相关(HR 1.08;95%CI 1.04至1.11)。
- 与阿托伐他汀相比,瑞舒伐他汀与蛋白尿风险升高相关(HR 1.17;95%CI 1.10至1.25)。
- 与阿托伐他汀相比,瑞舒伐他汀与肾衰竭替代治疗风险升高相关(HR 1.15;95%CI 1.02至1.30)。
- 瑞舒伐他汀剂量越高,风险越高。
关键数值与推荐
- 当前说明书建议严重慢性肾脏病患者剂量减少(最大日剂量10 mg)。
- eGFR<30 ml/min per 1.73 m2者中44%处方高剂量瑞舒伐他汀(每日20或40 mg)。
临床怎么用
- 作者认为在处方和监测瑞舒伐他汀时需要更加谨慎,尤其是接受高剂量或患有严重慢性肾脏病的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite reports of hematuria and proteinuria with rosuvastatin use at the time of its approval by the US Food and Drug Association (FDA), little postmarketing surveillance exists to assess real-world risk. Current labeling suggests dose reduction (maximum daily dose of 10 mg) for patients with severe CKD. METHODS: Using deidentified electronic health record data, we analyzed 152,101 and 795,799 new users of rosuvastatin and atorvastatin, respectively, from 2011 to 2019. We estimated inverse probability of treatment-weighted hazard ratios (HRs) of hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) associated with rosuvastatin. We reported the initial rosuvastatin dose across eGFR categories and evaluated for a dose effect on hematuria and proteinuria. RESULTS: Overall, we identified 2.9% of patients with hematuria and 1.0% with proteinuria during a median follow-up of 3.1 years. Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria (HR, 1.08; 95% confidence interval [95% CI], 1.04 to 1.11), proteinuria (HR, 1.17; 95% CI, 1.10 to 1.25), and KFRT (HR, 1.15; 95% CI, 1.02 to 1.30). A substantial share (44%) of patients with eGFR <30 ml/min per 1.73 m2 was prescribed high-dose rosuvastatin (20 or 40 mg daily). Risk was higher with higher rosuvastatin dose. CONCLUSIONS: Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria, proteinuria, and KFRT. Among patients with eGFR <30 ml/min per 1.73 m2, 44% were prescribed a rosuvastatin daily dose exceeding the FDA's recommended 10 mg daily dose. Our findings suggest the need for greater care in prescribing and monitoring rosuvastatin, particularly in patients who receive high doses or who have severe CKD.
引用
- Shin JI, Fine DM, Sang Y, et al. Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria. J Am Soc Nephrol. 2022. PMID: 35853713. doi:10.1681/ASN.2022020135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。